Specialty plastics Engineer with 15+ years’ experience in operations management strengthens Sharps senior leadership team and supports technical innovation and manufacturing through the Company’s ongoing transition to commercial operations
NEW YORK - Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, appoints Justin Page as Vice President of Technical Operations.
In his role, Mr. Page will be responsible for managing all aspects of Sharps' engineering operations. His primary focus will be to provide the leadership and technical expertise to support the prefillable syringe collaboration with Nephron Pharmaceuticals at the InjectEZ facility. These efforts will include the support for the injection molding of the specialty components and the high speed assembly of the prefillable syringe systems for all products. His initial efforts will include the acceleration of the manufacturing requirements that will produce the 1ml-long syringe platform and the 10ml syringe product that will begin production later this year. He will help oversee all training and manufacturing development programs to support the rapid startup of the various manufacturing cells for all products at the InjectEZ facility. Mr Page will also support Sharps’ broader technical operations including the optimization and increased throughput at both the InjectEZ facility and the operation in Hungary.
Robert Hayes, Chief Executive Officer, commented: “Justin has a strong background in plastics engineering and brings over 20 years of experience overseeing technical aspects of injection molding including the medical device industry. I have worked with Justin and the teams he has brought together over the years and I consider him to be an expert in his field. He will bring the technical expertise needed to support the advancement of our products through the collaboration with Nephron. As we enter into commercial sales and the next generation of our products, Justin will play a major role in our success.”
Mr. Page brings 20 years of technical injection molding and manufacturing experience in specialty packaging within the medical device industry. Mr. Page has spent the last 12 years with the Silgan Holdings Group where he served most recently as the Plant Manager overseeing all aspects of technical and manufacturing operations. Prior to Silgan, Mr. Page worked at Amcor Plastics where he managed injection molding processes for large scale medical device tool manufacturing. Mr. Page has a Bachelor’s of Science Degree in Plastics Engineering Technology from Penn State, Behrend College School of Engineering.
About Sharps Technology
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and ready to use processing. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US. For additional information, please visit www.sharpstechnology.com.
Forward-Looking Statements:
This press release contains “forward-looking statements” Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Investor Relations:
US Investor Relations:
Adam Holdsworth, Managing Director
TraDigital IR
Or
Investor Relations:
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
STSS@redchip.com
